Castle Biosciences (CSTL) Non-Current Receivables (2018 - 2025)
Castle Biosciences (CSTL) has disclosed Non-Current Receivables for 8 consecutive years, with $1.9 million as the latest value for Q4 2025.
- Quarterly Non-Current Receivables rose 104.58% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 104.58% year-over-year, with the annual reading at $1.9 million for FY2025, 104.58% up from the prior year.
- Non-Current Receivables hit $1.9 million in Q4 2025 for Castle Biosciences, down from $2.0 million in the prior quarter.
- In the past five years, Non-Current Receivables ranged from a high of $2.0 million in Q3 2025 to a low of $918000.0 in Q4 2024.
- Historically, Non-Current Receivables has averaged $1.3 million across 5 years, with a median of $1.2 million in 2023.
- Biggest five-year swings in Non-Current Receivables: decreased 22.92% in 2024 and later soared 104.58% in 2025.
- Year by year, Non-Current Receivables stood at $1.3 million in 2021, then dropped by 16.9% to $1.1 million in 2022, then rose by 9.57% to $1.2 million in 2023, then fell by 22.92% to $918000.0 in 2024, then soared by 104.58% to $1.9 million in 2025.
- Business Quant data shows Non-Current Receivables for CSTL at $1.9 million in Q4 2025, $2.0 million in Q3 2025, and $1.1 million in Q2 2025.